Alpha Cognition Plans Investor Call to Review ZUNVEYL Launch Strategy
Alpha Cognition Inc., a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative disorders, announced today that it will host an investor update call on Tuesday, January 28, 2025, at 4 PM EST. The call will outline the commercial launch strategy for ZUNVEYL (benzgalantamine), an FDA-approved treatment for mild-to-moderate Alzheimer’s disease (AD). The discussion will focus on the company’s plans to meet the needs of a growing patient population within the U.S. long-term care market.
Alpha Cognition Plans Investor Call to Review ZUNVEYL Launch Strategy